Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Forecast: What Value Will The Market Reach By 2030?
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market has experienced significant expansion in recent years. It is projected to increase from $0.59 billion in 2025 to $0.78 billion in 2026, at a compound annual growth rate (CAGR) of 32.7%. This market’s historical growth can be ascribed to breakthroughs in targeted cancer therapy research, a rising incidence of multiple myeloma cases, the expansion of monoclonal antibody development initiatives, enhancements in clinical trial infrastructure, and increasing investments in oncology drug discovery.
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market is projected to experience substantial expansion over the coming years. This market is anticipated to reach $2.42 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 32.9%. Factors driving this growth during the forecast period include a surge in regulatory approvals for targeted biologics, an escalating demand for personalized cancer treatments, the broadening of next-generation immunotherapy platforms, heightened investments in precision medicine ecosystems, and the wider acceptance of biomarker-based therapy selection. Key trends expected over the forecast period encompass the progressive development of bispecific antibody therapies, an increased emphasis on gprc5d biomarker-guided patient selection, the expanding use of CAR-T cell platforms, an enlargement of precision oncology clinical pipelines, and improved integration of companion diagnostics.
Get A Free Sample Report With In-Depth Market Insights:
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Growth Factors Behind Sustained Expansion
The increasing occurrence of myeloma is anticipated to stimulate expansion in the GPRC5D-targeted therapies market. Myeloma represents a form of cancer affecting plasma cells within the bone marrow, which interferes with typical blood cell generation and may lead to issues such as bone degradation, anemia, and renal dysfunction. The prevalence of myeloma is on the rise, partly attributable to aging demographics, given that the likelihood of developing plasma cell disorders increases with advancing age as genetic alterations gather over time. GPRC5D-targeted therapies are effective in managing myeloma by attaching to the GPRC5D protein found on cancerous plasma cells, subsequently instructing the immune system, particularly T cells, to specifically eliminate these malignant cells while largely preserving healthy ones. For example, in January 2026, data from the American Cancer Society, a US-based professional body, indicates that the United States is projected to register approximately 36,000 new cases of multiple myeloma in 2026, encompassing 20,150 cases in men and 15,850 cases in women, with an estimated 10,850 deaths expected, including 5,780 men and 5,070 women. Consequently, the increasing incidence of myeloma is fueling the expansion of the GPRC5D-targeted therapies market.
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Segmentation And Category Overview
The g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market covered in this report is segmented –
1) By Therapy Type: Monoclonal Antibodies; Bispecific Antibodies; Chimeric Antigen Receptor (CAR-T) Cell Therapies; Other Therapy Types
2) By Indication: Multiple Myeloma; Solid Tumors; Other Indications
3) By Technology: Precision Medicine Approaches; Molecular Targeted Therapy; Cancer Immunotherapy Platforms; Biopharmaceutical Drug Delivery Systems
4) By Route Of Administration: Intravenous; Subcutaneous; Other Routes Of Administration
5) By End-User: Hospitals; Specialty Clinics; Research Institutes; Other End-Users
Subsegments:
1) By Monoclonal Antibodies: Fully Human Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Murine Monoclonal Antibodies
2) By Bispecific Antibodies: Dual Targeting Bispecific Antibodies; Cross Linking Bispecific Antibodies; Immune Cell Engaging Bispecific Antibodies; Cytotoxic Bispecific Antibodies
3) By Chimeric Antigen Receptor (CAR-T) Cell Therapies: Autologous Car T Cell Therapies; Allogeneic Car T Cell Therapies; Next Generation Car T Cell Therapies; Gene Edited Car T Cell Therapies
4) By Other Therapy Types: Targeted Small Molecule Drugs; Receptor Specific Inhibitors; Injectable Biologics; Oral Targeted Therapeutics
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Industry Trends Fueling Future Revenue Growth
Companies in the GPRC5D targeted therapies market are concentrating on innovative solutions like bispecific T cell engagers to improve immune targeting of cancer cells and overall treatment efficacy. A bispecific T-cell engager (BiTE) is an immunotherapy molecule crafted to directly link T-cells to cancer cells, simultaneously binding both to activate T-cells for destroying the targeted cells. For instance, in August 2023, Johnson & Johnson, a US-based healthcare company, secured approval from the European Commission for TALVEY (talquetamab), Janssen’s bispecific antibody therapy, which targets GPRC5D and is indicated for relapsed and refractory multiple myeloma (RRMM) in patients after at least three prior therapies. This medication is a pioneering bispecific T-cell engager, specifically designed to target GPRC5D on multiple myeloma cells and CD3 on T cells for treating relapsed/refractory multiple myeloma in heavily pretreated patients. Its key purpose is to provide durable responses (ORR >70% in trials) following at least four prior therapies, offering advantages such as subcutaneous dosing, sustained quality-of-life benefits, and efficacy even post-bispecifics or CAR-T, thereby addressing an unmet need in late-line disease.
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Competitive Overview And Top Companies
Major companies operating in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market are Johnson And Johnson, F. Hoffmann-La Roche AG., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Bristol Myers Squibb Company, Genmab A/S, Genentech Inc., Simcere Zaiming Biotechnology Co. Ltd., Innovent Biologics Inc., Essen Biotech Co. Ltd., Nanjing IASO Biotechnology Co. Ltd., CARsgen Therapeutics Holdings Limited, Oricell Therapeutics Co. Ltd., Integral Molecular Inc., Overland Therapeutics Inc., Qilu Pharmaceutical Co. Ltd., Leads Biolabs Ltd., ShanghAI Yake Biotechnology Co. Ltd., Guangzhou Bio-gene Technology Co. Ltd.
View The Full G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Report:
G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) Targeted Therapies Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the GPRC5D targeted therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the g protein-coupled receptor family c group 5 member d (gprc5d) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
